SNCA and Parkinson disease: The aims of this study were to assess: (1) whether daily treatment with golexanolone improves motor symptoms (motor coordination and locomotor gait) and non-motor symptoms (cognitive function, fatigue, anxiety, and depression) in the 6-OHDA rat model of PD and (2) whether these improvements are associated with reductions in microglia and astrocyte activation, enhancements in TH expression in the striatum, and decreases in alpha-synuclein content.